BARD1 Life Sciences raises $15 million to accelerate cancer diagnostic test development
Chairman Dr Geoff Cumming said: “The capital raising was strongly supported by new and existing institutional and sophisticated investors with a deep understanding of the biotechnology sector and importance of early cancer detection on patient outcomes.”
Shareholders will be offered the opportunity to participate in a Share Purchase Plan to raise up to a further $2 million.
BARD1 Life Sciences Ltd has raised $15 million in a placement to sophisticated, institutional and professional investors to accelerate the development and commercialisation of its cancer diagnostic test development program.
The company has completed the placement with strong demand from new and existing, institutional and sophisticated investors in Australia and Hong Kong.